Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
092040
vs
K
KOSPI 200
Over the past 12 months, Amicogen Inc has underperformed KOSPI 200, delivering a return of -74% compared to KOSPI 200's +125% growth.
Stocks Performance
092040 vs KOSPI 200
Performance Gap
092040 vs KOSPI 200
Performance By Year
092040 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Amicogen Inc
Glance View
Amicogen is a biotechnology company that makes industrial enzymes and other bio-based ingredients. It uses microbes and fermentation to produce products that help customers make medicines, food ingredients, health supplements, cosmetics, and animal feed. In simple terms, it sits in the middle of the biotech supply chain and turns biological processes into commercial ingredients. The company sells these products to pharmaceutical companies, food and nutrition makers, and other industrial customers that need specialized enzyme or microbial-based materials. It also works on development projects tied to drug ingredients and other biotech materials, which can bring in revenue through product sales, development work, and related licensing or supply agreements. What makes Amicogen different is that it is not a consumer brand or a broad drugmaker. Its business is built around technical know-how in fermentation and enzyme production, where customers often need a very specific ingredient or process rather than a standard off-the-shelf product. That gives the company a niche role as a behind-the-scenes supplier for other industries.